UK Functional Genomics Research Receives Major Boost with £28.5 Million Funding

The landscape of functional genomics research in the UK is set to undergo a significant transformation, thanks to a substantial £28.5 million funding injection from the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC). This funding aims to propel the Human Functional Genomics Initiative programme, designed to deepen our understanding of how genomic variations influence human physiology over time and in various disease contexts.

At the helm of this groundbreaking initiative is Professor Jonathan Mill from the University of Exeter Medical School. As the newly appointed Director, Professor Mill will spearhead efforts to coordinate and integrate data within the functional genomics landscape. His leadership will be pivotal in fostering collaboration both nationally and internationally, ensuring that the initiative aligns with broader scientific goals and innovations.

The funding is allocated to maximize impact across various facets of the initiative:

• Director’s Award (£4.6 million): This fund will support data coordination, networking, and fostering collaborations across interdisciplinary research clusters and with external partners.
• Functional Genomics Screening Laboratory (£7 million): This portion will establish a state-of-the-art laboratory at the Milner Therapeutics Institute (MTI) in collaboration with AstraZeneca and the University of Cambridge. The lab will initially focus on non-cancerous diseases, with potential expansion into other areas.
• Research Clusters (£16.9 million): Four distinct research clusters will drive innovation in technology development and explore genomic variation in various disease areas.

Professor Mill emphasized the initiative’s potential to revolutionize our understanding of health and disease mechanisms. By identifying causal genomic variants and modeling their impact in disease-relevant cell types, the initiative aims to foster innovation and multidisciplinary collaboration. This approach promises to accelerate the translation of functional genomics research into practical health benefits, paving the way for new diagnostics and treatments.

The new functional genomics screening laboratory at MTI, overseen by Dr. Nicola McCarthy, will be a cornerstone of the initiative. It will enable collaborative CRISPR genetic screening and initially focus on immune, cardiovascular, neuronal, and respiratory systems. This laboratory will support researchers across the UK by covering screening costs and providing technical expertise, thus fostering a collaborative research environment.

Four specialized research clusters will tackle different aspects of genomic research:

1. Edinburgh Molecular Mechanisms Cluster: Led by Professor Kenneth Baillie at the University of Edinburgh, this cluster will utilize discarded surgical tissue for deep genetic and AI-driven disease characterization.
2. FGx-PTMv Cluster at Imperial College: Dr. Matthew Child’s team will study the biological consequences of genetic variants related to rare diseases, leveraging computational genomics and chemoproteomics.
3. Musculoskeletal Health Cluster at University of Oxford: Professor Dominic Furniss and his team will explore musculoskeletal health and disease, aiming to generate therapeutic targets and tools for broader use.
4. Brain Development Cluster at Kings College London: Professor Oscar Marin’s group will use brain organoid models to investigate gene variations leading to neurodevelopmental disorders.

Professor Patrick Chinnery, MRC Executive Chair, expressed optimism about the future of UK functional genomics research. The convergence of advanced gene-editing technologies, artificial intelligence, and other innovations supported by this funding will enable researchers to tackle previously insurmountable questions.